Last checked at 12 Oct 2021 07:00
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Completion of acquisition, Admission & TVR Update
Capitalised terms in this announcement carry the same meaning as in theRNS of 28 September 2021, unless otherwise stated
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that, further to the announcement on 28 September, the Acquisition of ADL Health has completed.
Admission of the Consideration Shares to trading on AIM and Total Voting Rights
Application has been made for admission of 8,937,337 Consideration Shares to trading on the AIM Market of the London Stock Exchange ("Admission") based on an exchange rate of US$1.37115:£1. Admission is expected to take place on 14 October 2021.
The Consideration Shares will, when issued, be credited as fully paid new ordinary shares and will rank equally in all respects with the existing ordinary shares, including the right to receive any dividend or other distribution declared, made or paid after Admission.
For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), the issued ordinary share capital of the Company following Admission will consist of 463,930,564 ordinary shares each carrying one voting right. There are no ordinary shares held in treasury. From the date of Admission, the figure of 463,930,564 may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the DTRs.
For further information please contact:
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
Mike Salter, CEO | Via Walbrook PR | |
Singer Capital Markets (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7496 3000 | |
Aubrey Powell / George Tzimas / Tom Salvesen | ||
Investec Bank plc (Joint Broker) | Tel: +44 (0)20 7597 4000 | |
Gary Clarence / Daniel Adams | ||
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | |
Paul McManus / Lianne Cawthorne | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 | |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.